Guangdong Hybribio BiotechLtd Future Growth
Future criteria checks 3/6
Guangdong Hybribio BiotechLtd is forecast to grow earnings at 78.4% per annum. EPS is expected to grow by 80.6% per annum.
Key information
78.4%
Earnings growth rate
80.6%
EPS growth rate
| Biotechs earnings growth | 42.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | 03 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Oct 08
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Sep 29Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065
May 22There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings
May 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 864 | -294 | -16 | 174 | N/A |
| 6/30/2024 | 907 | -59 | -22 | 214 | N/A |
| 3/31/2024 | 985 | 61 | -92 | 186 | N/A |
| 12/31/2023 | 1,104 | 140 | -66 | 320 | N/A |
| 9/30/2023 | 2,189 | 410 | 195 | 792 | N/A |
| 6/30/2023 | 3,361 | 871 | 313 | 1,012 | N/A |
| 3/31/2023 | 4,388 | 1,292 | 543 | 1,259 | N/A |
| 1/1/2023 | 5,597 | 1,726 | 575 | 1,309 | N/A |
| 9/30/2022 | 4,940 | 1,693 | 360 | 1,080 | N/A |
| 6/30/2022 | 4,217 | 1,439 | 294 | 994 | N/A |
| 3/31/2022 | 3,574 | 1,180 | 91 | 801 | N/A |
| 1/1/2022 | 2,673 | 852 | -10 | 631 | N/A |
| 9/30/2021 | 2,429 | 736 | -110 | 449 | N/A |
| 6/30/2021 | 2,148 | 625 | -181 | 276 | N/A |
| 3/31/2021 | 1,814 | 515 | -78 | 286 | N/A |
| 12/31/2020 | 1,354 | 363 | 24 | 311 | N/A |
| 9/30/2020 | 1,129 | 316 | 19 | 184 | N/A |
| 6/30/2020 | 918 | 216 | -75 | 135 | N/A |
| 3/31/2020 | 742 | 150 | -106 | 89 | N/A |
| 12/31/2019 | 729 | 147 | -84 | 113 | N/A |
| 9/30/2019 | 693 | 141 | -86 | 104 | N/A |
| 6/30/2019 | 648 | 128 | -58 | 89 | N/A |
| 3/31/2019 | 610 | 119 | -62 | 90 | N/A |
| 12/31/2018 | 580 | 114 | -64 | 80 | N/A |
| 9/30/2018 | 548 | 107 | -65 | 68 | N/A |
| 6/30/2018 | 518 | 102 | N/A | 73 | N/A |
| 3/31/2018 | 499 | 96 | N/A | 72 | N/A |
| 12/31/2017 | 479 | 93 | N/A | 79 | N/A |
| 9/30/2017 | 455 | 89 | N/A | 79 | N/A |
| 6/30/2017 | 431 | 80 | N/A | 59 | N/A |
| 3/31/2017 | 411 | 77 | N/A | 67 | N/A |
| 12/31/2016 | 398 | 76 | N/A | 64 | N/A |
| 12/31/2015 | 345 | 65 | N/A | 48 | N/A |
| 12/31/2014 | 264 | 63 | N/A | 35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300639 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 300639 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 300639 is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if 300639's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 300639's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 300639's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 10:31 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangdong Hybribio Biotech Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hanqing Zhu | Guosen Securities Co., Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |